UNSPSC 51322007: Colestipol hydrochloride

This classification denotes an anti-lipidemic agent with the molecular formula ((C3H5ClO)mon(C4H13N3)mon)co. ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X7D10K905G, chemically known as copolymer of diethylenetriamine and 1-chloro-2,3-epoxypropane, hydrochloride (with approximately 1 out of 5 amine nitrogens protonated) but more generally known as colestipol hydrochloride, which bears US NIH Compound Identifier 3084661.

UNSPSC 51322007 Colestipol hydrochloride is a Commodity code representing a specific pharmaceutical active ingredient purchased by state and local health agencies, primarily through emergency medical services procurement, state pharmacy benefit programs, and cooperative purchasing alliances. State and local governments buy colestipol hydrochloride and related pharmaceutical products as components of broader emergency life support medication supplies, generic multi-source pharmaceutical contracts, and direct-to-manufacturer prescription programs. Issuing bodies include municipal fire and rescue departments (via city purchasing offices), state health and human services commissions managing pharmacy benefits, and multistate cooperative purchasing alliances coordinating procurement for state and local member agencies. The City of Tampa's fire rescue program and the Texas Health and Human Services Commission represent the institutional buyers most active in recent opportunities; cooperative purchasing mechanisms such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) aggregate demand across multiple state and local jurisdictions to achieve volume pricing and supply chain efficiency.

Recent activity spans Florida, Texas, and Minnesota-centered cooperatives. The City of Tampa's Purchasing Department issued IFB No. 26P00188 in April 2026 for Advanced Life Support Medications (response due April 8, 2026) with an estimated contract value of $40,000, seeking four medication line items including vasopressors and cardiac agents for Tampa Fire Rescue in Hillsborough County; the solicitation carried a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount not to exceed $10,000. The Texas Health and Human Services Commission issued RFI No. HHS0017013 in March 2026 as exploratory market intelligence on direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager channels, with no budget disclosed. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across multiple state and local member facilities in Minnesota and Oregon, requiring NDC-level detail, cGMP and DSCSA compliance, and pricing through authorized wholesalers with contract effectiveness July 1, 2026.